Results and adverse effect evaluations in localized prostate cancer patients undergoing intensity modulated radiotherapy with tomotherapy

Year 2021, Volume: 3 Issue: 2, 73 - 79, 29.04.2021

Gül Ayşen Öztürk , Murat Ozturk

https://doi.org/10.46310/tjim.871471

Abstract

Aim
To assess the dosimetric results and early and late adverse effects of radiotherapy with tomotherapy in localized prostate cancer patients.
Materials and Methods
Treatment results and early and late adverse effects in 60 patients who had undergone curative radiotherapy due to prostate cancer and who had been followed-up for at least 6 months in the post-treatment process were assessed retrospectively. 28 of the patients were in the low-intermediate risk group, whereas 32 of them were in the high-risk group. 74 Gy radiotherapy was delivered to the prostate with simultaneous integrated boost strategy, 60 Gy to seminal vesicles and 52 Gy to pelvic lymph nodes of the cases. Patients with at least 6 months of post-treatment follow-up were assessed in terms of early and late adverse effects.
Results
Twenty patients had grade 1 and two patients had grade 2 acute genitourinary toxicity, whereas 15 patients had grade 1 and 4 patients had grade 2 acute gastrointestinal toxicity. Twelve patients had grade 1 and 3 patients had grade 2 late genitourinary toxicity, 6 patients had grade 1 and two other patients had grade 2 and grade 3 late gastrointestinal toxicity. Biochemical recurrence developed in four patients. One of the patients with recurrence died in the 14th month of recurrence due to organ metastasis.
Conclusions
Image-guided dose-escalated radiotherapy with IMRT technique is a reliable method in prostate cancer treatment. Increased toxicity was not observed in the cases with lymph node irradiation despite the increased radiotherapy field.

Keywords

Prostate cancer, intensity modulated radiotherapy, acute-late toxicity

References

• Rawla P. Epidemiology of prostate cancer. World journal of oncology 2019; 10(2), 63.
• Mangar SA, Huddart RA, Parker CC, Dearnaley DP, Khoo VS, Horwich A. Technological advances in radiotherapy for the treatment of localised prostate cancer. European Journal of Cancer 2005; 41(6), 908-21.
• Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Zattoni F. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. European urology 2011; 59(1), 61-71.
• Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, Collette L. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. The lancet oncology 2010; 11(11), 1066-73.
• Hong TS, Ritter MA, Tome WA, Harari PM. Intensity-modulated radiation therapy: emerging cancer treatment technology. British journal of cancer 2005; 92(10), 1819-24.
• Yeoh EE, Botten R, Russo A, McGowan R, Fraser R, Roos D, Sun WM. Chronic effects of therapeutic irradiation for localized prostatic carcinoma on anorectal function. International Journal of Radiation Oncology* Biology* Physics 2000; 47(4), 915-24.
• Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, Rosen I. Prostate cancer radiation dose response: results of the MD Anderson phase III randomized trial. International Journal of Radiation Oncology* Biology* Physics 2002; 53(5), 1097-1105.
• Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Pollack A. Long-term results of the MD Anderson randomized dose-escalation trial for prostate cancer. International Journal of Radiation Oncology* Biology* Physics 2008; 70(1), 67-74.
• Pollack A, Zagars GK, Smith LG, Lee JJ, Von Eschenbach AC, Antolak JA, Rosen I. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. Journal of Clinical Oncology 2000; 18(23), 3904-11.
• Peeters ST, Heemsbergen WD, Koper PC, Van Putten WL, Slot A, Dielwart MF, Lebesque JV. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006; 24(13), 1990-96.
• Zietman AL, DeSilvio ML, Slater JD, Rossi CJ, Miller DW, Adams JA, Shipley WU. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. Jama 2005; 294(10), 1233-39.
• Burman C, Chui CS, Kutcher G, Leibel S, Zelefsky M, LoSasso T, Mohan R. Planning, delivery, and quality assurance of intensity-modulated radiotherapy using dynamic multileaf collimator: a strategy for large-scale implementation for the treatment of carcinoma of the prostate. International journal of radiation oncology, biology, physics 1997; 39(4), 863-73.
• Jani AB, Su A, Correa D, Gratzle J. Comparison of late gastrointestinal and genitourinary toxicity of prostate cancer patients undergoing intensity-modulated versus conventional radiotherapy using localized fields. Prostate cancer and prostatic diseases 2007; 10(1), 82-86.
• Zelefsky MJ, Fuks Z, Happersett L, Lee HJ, Ling CC, Burman CM, Skwarchuk M. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiotherapy and Oncology 2000; 55(3), 241-49.
• Nutting CM, Convery DJ, Cosgrove VP, Rowbottom C, Padhani AR, Webb S, Dearnaley DP. Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. International Journal of Radiation Oncology* Biology* Physics 2000; 48(3), 649-56.
• Luxton G, Hancock SL, Boyer AL. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate. International Journal of Radiation Oncology* Biology* Physics 2004; 59(1), 267-84.
• Cavey ML, Bayouth JE, Colman M, Endres EJ, Sanguineti G. IMRT to escalate the dose to the prostate while treating the pelvic nodes. Strahlentherapie und Onkologie 2005; 181(7), 431-41.
• Zietman AL, DeSilvio ML, Slater JD, Rossi CJ, Miller DW, Adams JA, Shipley WU. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. Jama 2005; 294(10), 1233-39.
• Dearnaley DP, Jovic G, Syndikus I, Khoo V, Cowan RA, Graham JD, Sydes MR. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. The lancet oncology 2014; 15(4), 464-73.
• Heemsbergen WD, Al-Mamgani A, Slot A, Dielwart MF, Lebesque JV. Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiotherapy and Oncology 2014; 110(1), 104-9.
• Beckendorf V, Guerif S, Le Prisé E, Cosset JM, Bougnoux A, Chauvet B, Bey P. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. International Journal of Radiation Oncology* Biology* Physics 2011; 80(4), 1056-63.
• Liauw SL, Weichselbaum RR, Rash C, Correa D, Al-Hallaq HA, Pelizzari CA, Jani AB. Biochemical control and toxicity after intensity-modulated radiation therapy for prostate cancer. Technology in cancer research & treatment 2009; 8(3), 201-6.
• Cahlon O, Zelefsky MJ, Shippy A, Chan H, Fuks Z, Yamada Y, Amols H. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. International Journal of Radiation Oncology* Biology* Physics 2008; 71(2), 330-37.
• De Meerleer G, Vakaet L, Meersschout S, Villeirs G, Verbaeys A, Oosterlinck W, De Neve W. Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients. International Journal of Radiation Oncology* Biology* Physics 2004; 60(3), 777-87.
• Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, Amols HI. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. International Journal of Radiation Oncology* Biology* Physics 2008; 70(4), 1124-29.
• Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, Leibel SA. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. International Journal of Radiation Oncology* Biology* Physics 2002; 53(5), 1111-16.
• Pollack A, Hanlon AL, Horwitz EM, Feigenberg SJ, Konski AA, Movsas B, Price Jr RA. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology* Biology* Physics 2006; 64(2), 518-26.
• Özdemir S, Öksüz DÇ, Ergen ŞA, Günel H, Karaçam SÇ, Dinçbaş FÖ, Koca S. Acute toxicity in prostate carcinoma patients treated with kv-CBCT guided IMRT/VMAT. TURKISH JOURNAL OF ONCOLOGY 2014; 29(3), 89-96.
• Heemsbergen WD, Peeters ST, Koper PC, Hoogeman MS, Lebesque JV. Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. International Journal of Radiation Oncology* Biology* Physics 2006; 66(1), 3-10.
• Al-Mamgani A, Heemsbergen WD, Peeters ST, Lebesque JV. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. International Journal of Radiation Oncology* Biology* Physics 2009; 73(3), 685-91.
• Arcangeli S, Saracino B, Petrongari MG, Gomellini S, Marzi S, Landoni V, Arcangeli G. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area. Radiotherapy and Oncology 2007; 84(2), 148-55.
• Chung HT, Xia P, Chan LW, Park-Somers E, Roach III M. Does image-guided radiotherapy improve toxicity profile in whole pelvic-treated high-risk prostate cancer? Comparison between IG-IMRT and IMRT. International Journal of Radiation Oncology* Biology* Physics 2009; 73(1), 53-60.
• Jain S, Loblaw DA, Morton GC, Danjoux C, Szumacher E, Chu W, Cheung PC. The effect of radiation technique and bladder filling on the acute toxicity of pelvic radiotherapy for localized high risk prostate cancer. Radiotherapy and Oncology 2012; 105(2), 193-97.
• Hoffman KE, Voong KR, Levy LB, Allen PK, Choi S, Schlembach PJ, Kuban DA. Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology 2018; 36(29), 2943-49